Statins in the Prevention of Cardiovascular Events in Patients with Renal Failure

Title: Statins in the Prevention of Cardiovascular Events in Patients with Renal Failure

Volume: 7 Issue: 1

Author(s): Michele Buemi, Fulvio Floccari, Lorena Nostro, Susanna Campo, Chiara Caccamo, Alessio Sturiale, Carmela Aloisi, Maria Stella Giacobbe and Nicola Frisina

Affiliation:

Keywords: Cardiovascular disease (CVD), HMG-Coenzyme A reductase Inhibitors, Dialysis, transplantation, nephropathic patients

Abstract: HMG-CoA reductase inhibitors (statins) are among the most widely used hypolypemizing drugs with a pleiotropic activity. Numerous clinical trials have demonstrated that statins can have a significant effect in the prevention of cardiovascular diseases in the general population. In patients with renal failure, this drug preserves the hypolypemizing efficacy found in the general population without increasing their unwanted side-effects. The re-analysis of data from epidemiological studies conducted on the general population has confirmed that statins provide cardiovascular protection also in subjects with renal failure. These data have been partly confirmed by the findings made by 4D (Die Deutsche Diabetes Dialyse Studie) and Alert studies, conducted on diabetic patients on dialysis and patients with renal transplants, respectively. The results of other studies, such as AURORA, SHARP, REnal and Vascular End stage Disease, and ESPLANADE, clearly indicate that statins prevent cardiovascular disease in patients with renal insufficiency, just as they do in the general population.

Cite this article as:

Buemi Michele, Floccari Fulvio, Nostro Lorena, Campo Susanna, Caccamo Chiara, Sturiale Alessio, Aloisi Carmela, Stella Giacobbe Maria and Frisina Nicola, Statins in the Prevention of Cardiovascular Events in Patients with Renal Failure, Cardiovascular & Hematological Disorders-Drug Targets 2007; 7 (1) . https://dx.doi.org/10.2174/187152907780059119